INmune Bio's Alzheimer's Trial Featured as 'Successful Example' at Major Conference, Advances to Phase 2b/3
INMB is trading near its 52-week low of $1.16 (15% above the low).
Summary
INmune Bio's Phase 2 MINDFuL trial for XPro™ in early Alzheimer's disease was prominently featured as a successful example at the AD/PD 2026 international conference by a leading neuroimmunologist. The presentation highlighted the trial's effective biomarker enrichment strategy and consistent efficacy signals. Critically, the company also announced positive alignment with the FDA to advance XPro™ into an integrated Phase 2b/3 registrational program. This news provides significant external validation for INmune Bio's clinical approach and drug candidate, substantially de-risking its development path. Investors will now closely monitor the initiation and progress of the registrational trial.
At the time of this announcement, INMB was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33M. The 52-week trading range was $1.16 to $11.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.